Glycine, N,N-dimethylglycyl-L-seryl-L-cysteinyl- | 259198-91-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: Glycine, N,N-dimethylglycyl-L-seryl-L-cysteinyl-
• 英文别名: 2-[[(2R)-2-[[(2S)-2-[[2-(dimethylamino)acetyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]acetic acid
• CAS: 259198-91-9
• 化学式: C₁₂H₂₂N₄O₆S
• 分子量: 350.396
• InChiKey: QHKPTNDWCHVORR-YUMQZZPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.7
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  149
• 氢给体数：
  6
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  n-butylammonium tetrachlorooxotechnetate(V) 、 Glycine, N,N-dimethylglycyl-L-seryl-L-cysteinyl- 在 氢氧化钾 、 sodium acetate 作用下， 以 甲醇 、 水 、 乙腈 为溶剂， 以21%的产率得到TcODMG-Ser-Cys-GlyOH
  参考文献：
  名称：

  The solid phase synthesis and NMR spectroscopy of a 99Tc chelate–bombesin derived peptide conjugate

  摘要：

  A bombesin derived peptide-(TC)-T-99 chelate conjugate was prepared using a solid phase synthetic methodology. The reported approach involved linking a prefabricated bifunctional N2N'S technetium chelate complex to a resin bound peptide sequence derived from bombesin, which has been shown to bind to the gastrin-releasing peptide (GRP) receptor. The technetium chelate-peptide conjugate was subsequently isolated from the solid support and characterized by electrospray mass spectrometry, HPLC and NMR spectroscopy. The goal of the approach was to develop a versatile solid phase synthetic procedure that would facilitate the future application of modern drug discovery techniques for the development of receptor selective technetium radiopharmaceuticals, Furthermore, the NMR studies of the reported radiometal-peptide conjugate provide an important reference for the characterization of future bombesin-based radiopharmaceuticals. (C) 2001 Elsevier Science B.V. All rights reserved.

  DOI：

  10.1016/s0020-1693(01)00637-5
• 作为产物：
  描述：

  dimethylglycylserinylcysteinyl(Acetomidomethyl)glycine 、 、 水 在 硫化氢 、 水 作用下， 以 溶剂黄146 为溶剂， 反应 3.05h， 生成 Glycine, N,N-dimethylglycyl-L-seryl-L-cysteinyl-
  参考文献：
  名称：

  Immobilized labeling compounds and methods

  摘要：

  这项发明涉及将金属用于标记共轭物的方法和化合物，包括以下步骤：将共轭物耦合到支持表面上；向支持体中引入形成复合物的金属；并收集从支持体释放的金属-共轭物复合物。金属在复合物形成时催化共轭物从支持体上解离，从而得到几乎不含未标记共轭物的溶液。

  公开号：

  US07320784B1

文献信息

• Conjugates of antioxidants with metal chelating ligands for use in diagnostic and therapeutic allications
  申请人：——

  公开号：US20040082767A1

  公开（公告）日：2004-04-29

  The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes.

  本发明提供了用于诊断和治疗应用的放射性药物、抗氧化剂与金属螯合配体的结合物、中间化合物、制备这种放射性药物、配体和中间化合物的方法，以及用于制备放射性药物复合物的试剂盒。
• CONJUGATES OF ANTIOXIDANTS WITH METAL CHELATING LIGANDS FOR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
  申请人：Ranganathan S. Ramachandran

  公开号：US20070086944A1

  公开（公告）日：2007-04-19

  The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes.

  该发明提供了用于诊断和治疗应用的放射性药物、抗氧化剂与金属螯合配体的结合物、中间化合物、制备这种放射性药物、配体和中间化合物的方法，以及用于制备放射性药物复合物的试剂盒。
• Linkers for radiopharmaceutical compounds
  申请人：De Haën Christoph

  公开号：US20060241018A1

  公开（公告）日：2006-10-26

  A new and improved method for extending the half life of pharmaceutical compounds for use in diagnostic imaging or therapy uses a novel linker to attach a diagnostic or therapeutic moiety to a targeting peptide or another diagnostic or therapeutic moiety. The resulting compound may have the general formula M-N-O-P-Q, wherein M is the diagnostic or therapeutic moiety, N-O-P is the linker of the present invention, and Q is the targeting peptide. In another embodiment the compounds may have the formula M-N-O-P-M, wherein M is independently a diagnostic or therapeutic moiety and N-O-P is the linker of the invention. Methods for imaging or treating a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound are further provided. Methods for radiotherapy of a patient using the compounds are further provided, as are methods for preparing a radiotherapeutic agent from the compounds.

  一种新的、改进的方法，用于延长药物化合物的半衰期，用于诊断成像或治疗，使用一种新型连接剂将诊断或治疗基团连接到靶向肽或另一个诊断或治疗基团上。得到的化合物可能具有一般公式M-N-O-P-Q，其中M是诊断或治疗基团，N-O-P是本发明中的连接剂，而Q是靶向肽。在另一种实施方案中，化合物可能具有公式M-N-O-P-M，其中M是独立的诊断或治疗基团，N-O-P是该发明中的连接剂。还提供了使用该发明中化合物进行成像或治疗患者的方法。还提供了制备诊断成像剂的方法和试剂盒。还提供了使用该化合物进行放射治疗的方法，以及制备放射治疗剂的方法。
• Linkers For Radiopharmaceutical Compounds
  申请人：De Haen Christoph

  公开号：US20110280802A1

  公开（公告）日：2011-11-17

  A new and improved method for extending the half life of pharmaceutical compounds for use in diagnostic imaging or therapy uses a novel linker to attach a diagnostic or therapeutic moiety to a targeting peptide or another diagnostic or therapeutic moiety. The resulting compound may have the general formula M-N—O—P-Q, wherein M is the diagnostic or therapeutic moiety, N—O—P is the linker of the present invention, and Q is the targeting peptide. In another embodiment the compounds may have the formula M-N—O—P-M, wherein M is independently a diagnostic or therapeutic moiety and N—O—P is the linker of the invention. Methods for imaging or treating a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound are further provided. Methods for radiotherapy of a patient using the compounds are further provided, as are methods for preparing a radiotherapeutic agent from the compounds.

  一种改进的新方法，用于延长药物化合物的半衰期，以用于诊断成像或治疗，使用新型连接剂将诊断或治疗基团连接到靶向肽或另一个诊断或治疗基团上。所得化合物可能具有一般公式M-N-O-P-Q，其中M为诊断或治疗基团，N-O-P为本发明的连接剂，Q为靶向肽。在另一实施例中，化合物可能具有公式M-N-O-P-M，其中M独立地为诊断或治疗基团，N-O-P为本发明的连接剂。还提供了使用本发明化合物进行成像或治疗患者的方法。还提供了制备诊断成像剂的方法和工具包。还提供了使用化合物进行放射治疗的方法，以及制备放射治疗剂的方法。
• IMMOBILIZED LABELING COMPOUNDS AND METHODS
  申请人：Bracco International B.V.

  公开号：EP1154803B1

  公开（公告）日：2004-11-17